Étiquette : système endocannabinoïde

Cannabis and Depression, Daniel Feingold & Aviv Weinstein, 2021

Cannabis and Depression Daniel Feingold, Aviv Weinstein Advances in Experimental medicine and Biology, 2021, 1264, 67-80. In book : "Cannabinoids and Neuropsychiatric Disorders", Aviv Weinstein 's Lab Doi : 10.1007/978-3-030-57369-0_5 Abstract There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of [...]

Lire la suite

Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study, Sharon R. Sznitman et al., 2022

Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study Sharon R. Sznitman, David Meiri, Ben H. Amit, Dennis Rosenberg, Talya Greene Journal of Anxiety Disorders, 2022, 92, 102632 Doi : 10.1016/j.janxdis.2022.102632 Abstract Despite increasing use of Medical Cannabis (MC) among posttraumatic stress disorder(PTSD) patients, research is lacking on how MC treatment relates to PTSD symptomatology, in particular sleep disturbances. This study examines the time gap between MC use and sleep onset and its association with (1) number of awakenings throughout the night, (2) early awakenings, (3) nightmares. Each morning over a two week period, 77 licensed MC patients suffering from PTSD reported [...]

Lire la suite

Cannabinoids and Endocannabinoids, and Prospective Modulation of EC Signaling in Neurodegenerative, Cardiovascular and Allied Disorders, Vinod Nikhra, 2019

Cannabinoids and Endocannabinoids, and Prospective Modulation of EC Signaling in Neurodegenerative, Cardiovascular and Allied Disorders Dr Vinod Nikhra Preprint, May 2019 Doi : 10.13140/RG.2.2.36649.24165   ABSTRACT CANNABIS USE AND AVAILABILITY: The Cannabis derivatives have been used for recreational and medicinal purposes since ancient times. Because of the additive potential of cannabis products, their sale, possession and use are variously regulated in different countries throughout the world. Still as a psychoactive drug, cannabis continues to find extensive favour among recreational and medical users in the USA and other countries having led to decriminalise cannabis use for recreational and medicinal purposes. ECS: RECEPTORS, LIGANDS AND SIGNALING: The endocannabinoid system comprises [...]

Lire la suite

Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system ? A systematic review, John M McPartland et al., 2014

Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review John M McPartland, Marnie Duncan, Vincenzo Di Marzo and Roger G Pertwee British Journal of Pharmacology, 2015, 172, 737-753. Doi : 10.1111/bph.12944   Based upon evidence that the therapeutic properties of Cannabis preparations are not solely dependent upon the presence of Δ9-tetrahydrocannabinol (THC), pharmacological studies have been recently carried out with other plant cannabinoids (phytocannabinoids), particularly cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV). Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 [...]

Lire la suite

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review, Laura Orsolini et al., 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti  and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]

Lire la suite

Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort, Terri A. deRoon-Cassini et al., 2022

Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort Terri A. deRoon-Cassini, Carisa L. Bergner, Samantha A. Chesney, Nicholas R. Schumann, Tara Sander Lee, Karen J. Brasel and Cecilia J. Hillard Translational Psychiatry, 2022, 12, 48, 1-12. Doi : 10.1038/s41398-022-01808-1   The endocannabinoid signaling system (ECSS) regulates fear and anxiety. While ECSS hypoactivity can contribute to symptoms of established post-traumatic stress disorder (PTSD), the role of the ECSS in PTSD development following trauma is unknown. A prospective, longitudinal cohort study of 170 individuals (47% non-Hispanic Caucasian and 70% male) treated at a level 1 trauma [...]

Lire la suite

Fibromyalgia and the endocannabinoid system, John M. McPartland, 2010

Fibromyalgia and the endocannabinoid system John M. McPartland in Fibromyalgia syndrome : A practitioner’s guide to treatment, chapter 11, 2010, 263-277. Doi : 10.1016/B978-0-443-06936-9.00011-1   CHAPTER CONTENTS Introduction . . . . . . . . . . . . . . . 263 Cannabis and cannabinoid receptors . . 264 Endocannabinoids and their enzymes . 266 Nociception and pain . . . . . . . . . . 266 Around the edges of fibromyalgia . . . . 269 Enhancing the eCB system . . . . . . . 270 Other approaches . . . . . . . . . . . . 272 Conclusions . . . . [...]

Lire la suite

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder : From Bench Research to Confirmation in Human Trials, Rafael M. Bitencourt and Reinaldo N. Takahashi, 2018

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder : From Bench Research to Confirmation in Human Trials Rafael M. Bitencourt and Reinaldo N. Takahashi Frontiers in Neuroscience, 2018, 12, 502, 1-10. Doi : 10.3389/fnins.2018.00502   Post-traumatic stress disorder (PTSD) is characterized by poor adaptation to a traumatic experience. This disorder affects approximately 10% of people at some point in life. Current pharmacological therapies for PTSD have been shown to be inefficient and produce considerable side effects. Since the discovery of the involvement of the endocannabinoid (eCB) system in emotional memory processing, pharmacological manipulation of eCB signaling has become a therapeutic possibility for the treatment of [...]

Lire la suite

Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder, Matthew N. Hill et al., 2018

Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder Matthew N. Hill, Patrizia Campolongo, Rachel Yehuda and Sachin Pate Neuropsychopharmacology REVIEWS, 2018, 43, 80–102. doi : 10.1038/npp.2017.162   Exposure to stress is an undeniable, but in most cases surmountable, part of life. However, in certain individuals, exposure to severe or cumulative stressors can lead to an array of pathological conditions including posttraumatic stress disorder (PTSD), characterized by debilitating trauma-related intrusive thoughts, avoidance behaviors, hyperarousal, as well as depressed mood and anxiety. In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, [...]

Lire la suite

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior, Citlalli Netzahualcoyotzi et al., 2021

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior Citlalli Netzahualcoyotzi, Luis Miguel Rodríguez-Serrano, María Elena Chávez-Hernández and Mario Humberto Buenrostro-Jáuregui International Journal of Molecular Sciences, 2021, 22, 7450. doi : 10.3390/ijms22147450   Abstract The endocannabinoid system (ECS) is a crucial modulatory system in which interest has been increasing, particularly regarding the regulation of behavior and neuroplasticity. The adolescent–young adulthood phase of development comprises a critical period in the maturation of the nervous system and the ECS. Neurogenesis occurs in discrete regions of the adult brain, and this process is linked to the modulation of some behaviors. Since marijuana (cannabis) is the most consumed illegal [...]

Lire la suite